Clinical trial

A Study of SKB518 in Patients With Lung Cancer

NCT07019675

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-08-29

PhasePHASE2

Study timeline

Study start (actual)2025-08-29Date precision: day

Registry last updated2026-05-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Carcinomaunresolved

Interventions

SKB518DRUG

TislelizumabDRUG · verified · RxNorm: tislelizumab

CarboplatinDRUG · verified · RxNorm: carboplatin

Sponsors & collaborators

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.lead sponsor

Mapped research locations

WuhanHubei, China2 BeijingChina1 ShanghaiChina1 HangzhouZhejiang, China1 ChangshaHunan, China1 JinanShandong, China1 ZhengzhouHenan, China1 TianjinChina1 NanchangJiangxi, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07019675 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.